Can More People Be Put on ART Without Increased Cost?
With no end to the global funding retreat in sight, new strategies are required to change the way we provide treatment to the world's 33 million people infected with HIV.
On June 7-10, the Clinton Health Access Initiative (CHAI) hosted a conference, Opportunities to reduce the cost of anti-retroviral (ARV) treatment, to explore opportunities to significantly lower the costs of antiretroviral therapy (ART). Dose finding during drug development often maximizes tolerability but sometimes fails to explore minimally effective dosing. The earliest example of dose adjustment was AZT (zidovudine), which was initially tested at much higher doses (1500 mg daily compared with today's dose of 600 mg daily).1 Back in 1990, activists applied pressure to speed up the FDA's approval of AZT's use at the lower, safer, equally effective dose.2,3
With clinicians, pharmacologists, chemists, researchers, regulatory experts, and community advocates in attendance, discussions included reformulation, dosage optimization and manufacturing along with attendant issues of regulatory pathways and ethical considerations for optimized ARV regimens. If dose optimization and reformulations are proven to be safe, efficacious and significantly cheaper, many more people could be enrolled on first-line ART using existing funding flows -- in effect, more people on treatment for the same drug costs.
A significant step toward dose optimization is in motion with the Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy (ENCORE) study to evaluate reduced doses of efavirenz which is being conducted at the University of New South Wales, Australia. The study will be conducted through an international research network with sites in high-, middle- and low-income settings. Data are expected by mid-2013. If successful, this could set the stage for cheaper regimens, new fixed dose combinations and most importantly, more people on ART.
This article was provided by Treatment Action Group. It is a part of the publication TAGline.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)